Regulations

The FDA will not regulate CBD products as dietary supplements but the agency said it would “work with Congress” to establish rules for hemp-derived cannabinoid products, which are federally legal but remain unregulated.

New York’s Committee on Open Government said the state’s Office of Cannabis Management has not been following the state open meeting laws.

A real estate developer has filed suit against the city of Pontiac, Michigan and its clerk over the delayed enactment of local cannabis industry rules.

Multiple physicians’ organizations in Vermont are urging lawmakers to maintain THC potency caps in state-legal cannabis products — currently, flower products are capped at 30% THC potency and there is a 60% max potency for concentrates.

Michigan Gov. Gretchen Whitmer (D) vetoed three proposals related to cannabis at the end of 2022, claiming the bills were “rushed through a lame duck session.”

Kentucky’s limited medical cannabis reforms took effect on January 1, allowing patients with a doctor’s recommendation to possess up to eight ounces of medical cannabis if purchased legally in another state.

The Vermont Cannabis Control Board is recommending the state drop THC potency caps for cannabis concentrates, arguing the limits will create a black market monopoly and lead cannabis companies to dilute their products with potentially dangerous filler.

The Washington D.C. City Council gave unanimous and final approval to a medical cannabis reforms package, capping a nearly two-year journey for the bill from its proposal to passage.

The Washington state Liquor and Cannabis Board announced it is suspending the license of Port Angeles-based Dank Inc., claiming to have discovered “untagged” plants, evidence of potential cannabis product diversion, and other violations of state law.

Guam has now appointed 11 “responsible officials” to represent the island’s upcoming cannabis business entities but none have yet to formally submit their business application.

The Minnesota Board of Pharmacy filed a lawsuit against Northland Vapor — creator of the “Death By Gummy Bears” line of edibles — alleging that the company’s products far exceed the state’s strict THC potency limits.

New Jersey regulators have approved initial rules for cannabis consumption lounges in the state — a 60-day public comment period will follow before the rules can be officially finalized.

Colorado cannabis officials have adopted an industry regulations package that includes new cannabis storage requirements and “use-by” labels for cannabis product packaging.

The New York Medical Cannabis Industry Association said about 40% of products bought from unlicensed New York City cannabis shops tested positive for contaminants such as E. coli, lead, and salmonella.

The Oklahoma Medical Marijuana Authority is holding a public comment period for its proposal to make the state’s medical cannabis regulations permanent, including a moratorium on new cannabis business licenses.

Utah’s Department of Agriculture & Food asked lawmakers to ban synthetic cannabinoids from the state’s regulated medical cannabis market.

Kentucky Gov. Andy Beshear (D) has issued an executive order to permit certain patients with severe conditions to possess and consume medical cannabis that was purchased in a legal state.

Officials in Missouri have circulated draft rules for its adult-use cannabis industry with the aim of launching before February of next year.

The Czech Republic is seeking to coordinate its adult-use cannabis legalization law with Germany as the two countries embark on implementing the reforms. 

The Maine Office of Cannabis Policy has banned caregivers without a storefront from providing medical cannabis in the form of pre-rolls and liquid concentrates.

The U.S. Cannabis Council has launched a “Buy Legal” advertising campaign to encourage consumers to purchase cannabis products from regulated, legal sources.

New York officials have released the state’s regulations for adult-use cannabis sales by licensed dispensaries.

Mississippi’s medical cannabis program director said patients should have access to products in early 2023.

The Nevada Board of Pharmacy is not allowed to regulate cannabis and must remove it from its list of scheduled substances, according to a new district judge ruling.